Skip to main content

Table 3 TTC-related event rate > 34% according to proportion of toxicity

From: Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Expected overall adverse event (Proportion)

Adverse event rate (Null proportion)

Lower critical value

Power

5%

34%

1

88.2%

10%

34%

1

65.9%

15%

34%

1

44.3%

20%

34%

1

27.5%